This case highlights several key aspects in treating BRG-1-deficient lung cancer: the impact of partial BRG-1 deletion, the potential role of immunotherapy, the effects of concurrent KRAS G12C mutation, and the importance of comprehensive molecular analysis. This evidence concerns the gene KRAS and lung carcinoma.